Benzalkonium Chloride Induces Dephosphorylation of Myosin Light Chain in Cultured Corneal Epithelial Cells

Ying Guo, Minati Satpathy, Graeme Wilson, and Sangly P. Srinivas

PURPOSE. Phosphorylation of myosin light chain (MLC) is essential for the contractility of the actin cytoskeleton, which regulates barrier integrity, adhesion, and migration. This study was conducted to investigate the effect of benzalkonium chloride (BAK), a preservative in topical ophthalmic formulations, on MLC phosphorylation in primary cultures of bovine corneal epithelial cells (BCECs).

METHODS. MLC phosphorylation was assessed by urea-glycerol gel electrophoresis followed by Western blot analysis. Activation of RhoA, which inhibits MLC phosphatase through Rho kinase, was examined by immunoprecipitation. The release of adenosine triphosphate (ATP) was measured by the luciferase-luciferin bioluminescence technique.

RESULTS. Positive expression of MLC kinase (MLCK) was found at the mRNA and protein levels by RT-PCR and Western blot analysis, respectively. Exposure to BAK for 10 to 20 minutes at concentrations of 0.0005%, 0.001%, and 0.003% reduced MLC phosphorylation by more than 30%. In addition, BAK led to thinning of the cortical actin and a decrease in cell adhesion. However, RhoA activity was found to increase with BAK treatment. Similar to BAK, ATP-depletion (induced by both antimycin-A and hypoxia) led to MLC dephosphorylation. BAK exposure also showed acute ATP release.

CONCLUSIONS. BAK induces acute ATP release and concomitant MLC dephosphorylation in bovine corneal epithelial cells. The dephosphorylation, presumably due to ATP loss, is indicative of a loss of contractility of the actin cytoskeleton that could affect cellular functions contributing to the maintenance of epithelial barrier integrity. (Invest Ophthalmol Vis Sci. 2007; 48:2001-2008) DOI:10.1167/iobs.06-0013

The cationic surfactant benzalkonium chloride (BAK) is a common disinfectant in topical ophthalmic formulations. Its concentration varies from 0.004% to 0.02%. BAK has poor penetration across the cornea and mostly accumulates in the epithelium. Since the corneal epithelium forms a protective barrier on the ocular surface, any toxicity to the layer is damaging to the cornea. One major effect of BAK on the cornea epithelium is disruption of the barrier function. Other adverse effects include accelerated cell desquamation, compromised wound healing, and cessation of mitosis. However, the underlying mechanisms are not clear, although BAK has been found to induce a variety of cellular changes such as cell membrane damage, adenosine triphosphate (ATP) depletion, generation of oxidative stress, activation of AP-1 and NF-κB, and cell apoptosis.

The corneal epithelium undergoes a continuous self-renewal process to maintain its barrier integrity. The process involves continuous shedding of the superficial squamous cells followed by their replacement from deeper layers. Because mitotic activity occurs only in the basal epithelial cells, shedding of the superficial cells is balanced by cell proliferation and centripetal migration. In other words, accelerated desquamation and/or inhibited mitosis or migration can lead to a loss of cells in the superficial layers and can thereby adversely affect the barrier integrity of the epithelium. Alternatively, the barrier integrity can be disrupted by a breakdown of the interactions of the transmembrane proteins of tight junctions as shown for corneal endothelial and vascular endothelial monolayers. The tethering forces, which are a prerequisite for interactions of the transmembrane proteins, are sensitive to contractility of the cortical actin cytoskeleton. When the tone of this peripheral actin is increased, a centripetal force opposing the tethering forces is generated, leading to a breakdown of the barrier integrity. Since there is extensive involvement of actin contractility in the regulation of tight junctions, cell adhesion, and motility, we have examined the biochemical effects of BAK on the actin cytoskeleton in this study.

As in smooth muscle cells, contractility of the actin cytoskeleton in nonmuscle cells is regulated by phosphorylation of myosin light chain (MLC, 20 kDa). The extent of MLC phosphorylation is determined by two opposing pathways: MLC kinase (MLCK)-driven phosphorylation and MLC phosphatase (MLCP)-driven dephosphorylation. MLCK is a dedicated kinase for phosphorylating MLC and is activated when bound to the Ca2+-calmodulin complex. MLC is dephosphorylated by MLCP, a heterotrimeric complex consisting of the catalytic subunit (PP1c; 38 kDa), the myosin binding subunit (MYPT1; 130 kDa), and a small subunit of unknown function (M20; 20 kDa). Phosphorylation of MYPT1 by Rho kinase (at Thr-696 and Thr-850 residues) inhibits the phosphatase activity of PP1c. Rhokinase is an effector molecule for the small GTPase, RhoA. The RhoA-Rho kinase axis is well known to be activated in response to G protein-coupled receptors (GPCRs) coupled to G12/13 G proteins. PKC inactivates MLCP through phosphorylation of CPI-17 (the PKC-activated 17-kDa inhibitor protein of type 1 phosphatase; 17 kDa), which is known to inactivate PP1c. Thus, activation of Rho kinase and/or PKC results in contraction of the actin cytoskeleton.

To date, there have been no studies on MLC-regulated actin contractility in corneal epithelial cells. Examination of MLC phosphorylation in response to BAK may not only help ascertain the molecular mechanisms underlying the epithelial effects of the preservative, but may also bring forward the significance of actin contractility in maintenance of the barrier integrity of the epithelium.

From the School of Optometry, Indiana University, Bloomington, Indiana.

Supported by National Eye Institute Grant EY14415 (SPS) and by a Faculty Research Support Program award from the Office of the Vice Provost for Research at Indiana University.

Submitted for publication June 6, 2006; revised November 20, 2006; accepted March 16, 2007.

Disclosure: Y. Guo, None; M. Satpathy, None; G. Wilson, None; S.P. Srinivas, None

The publication costs of this article were defrayed in part by page charge payment. This article must therefore be marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact.

Corresponding author: Sangly P. Srinivas, 800 East Atwater Avenue, Indiana University, School of Optometry, Bloomington, IN 47405; srinivas@indiana.edu.
MATERIALS AND METHODS

Drugs and Chemicals

Bovine calf serum (BCS) was purchased from Hyclone (Logan, UT). All other cell culture supplies were from Invitrogen-Gibco (Grand Island, NY). Bovine α-thrombin and V-27632 were purchased from Calbiochem (La Jolla, CA) and Tocris (Ballwin, MO), respectively. Enhanced chemiluminescence reagent was purchased from GE Healthcare (Piscataway, NJ). Phalloidin conjugated to Texas red was obtained from Invitrogen-Molecular Probes (Eugene, OR). All other drugs and reagents were purchased from Sigma-Aldrich (St. Louis, MO).

Primary Culture of Bovine Corneal Epithelial Cells (BCECs)

Bovine eyes from a local abattoir were delivered on ice and dissected with 1% iodine. Corneal epithelium, along with a small thickness of stroma, was dissected using a scalpel and incubated in 2 U/mL Dispase at 37°C for 90 minutes. Epithelial sheets were then removed under a dissecting microscope and incubated further at 37°C in 0.05% trypsin. After 15 minutes, trypsin was deactivated by exposure to a growth medium containing 10% BCS. Cells were then collected by centrifugation. After the supernatant was discarded, cells were resuspended in DMEM/F12 culture medium supplemented with 10% BCS, 5 μg/mL insulin, 5 ng/mL epidermal growth factor, and an antibiotic–antimycotic mixture (50 μg/mL gentamicin and 50 ng/mL amphotericin B). Cells were cultured at 37°C in a humidified atmosphere containing 5% CO2 and 95% air. The medium was replaced on alternate days. The second- and third-passage cells were used for all experiments.

RT-PCR Assays

Total RNA was isolated from bovine corneal cells (BCECs; Trizol; Invitrogen-Gibco) and quantified by absorption at 260 nm. First-strand cDNA was synthesized for RT-PCR (SuperScript III Reverse Transcriptase; Invitrogen-Gibco). Sequences of the primers used for MLCK are 5'-ATGAAATCTCGAGGACATCCC-3' (forward [F]) and 5'-TGGTGGAGGAGGATGTCG-3' (reverse [R]). For RhoA, the primer sequences are 5'-TTGGCTGCGCATCGAGAGAAAATC-3' (F) and 5'-AGATCCTCTGGTCCCAAACG-3' (R); and for Rho kinase I, the sequences are 5'-TGGGTATTGAGGCGATGTTG-3' (F) and 5'-CAAGTCACAAAAATCTGCTAATCTA-3' (R). RT-PCR products were run on an agarose gel (1%) and visualized by ethidium bromide staining along with 100-bp and 1000-bp ladder molecular mass markers (GE Healthcare).

Expression of MLCK by Western Blot Analysis

A monoclonal antibody directed against chicken gizzard MLCK (K36; 1:5000), known to recognize human, bovine, and avian MLCK (both smooth muscle and vascular endothelial isoforms) was used. Cells grown on Petri dishes were lysed with an ice-cold lysis buffer containing 50 mM Tris-HCl (pH 7.6), 150 mM NaCl, 1% Triton X-100, 2 mM EGTA (pH 8.0), EDTA, dithiothreitol (DTT), phenylmethylsulfonyl fluoride (PMSF), Na2F, and a protease inhibitor cocktail (containing leupeptin, pepstatin, chymostatin, and aprotinin). After a preclarifying centrifugation step (14,000 rpm for 15 minutes at 4°C), the whole lysate was subjected to SDS-PAGE (100 μg protein/lane) and immunoblot analysis. Membranes were blocked with TBST containing 5% nonfat dry milk for 1 hour at room temperature (RT), and subsequently incubated with the primary antibody that had been diluted in TBST and dry milk overnight at 4°C. Blots were washed with TBST for three times (15 minutes each) and then visualized using the peroxidase-conjugated secondary antibody and chemiluminescence (ECL; GE Healthcare).

Quantitative Estimation of MLC Phosphorylation

MLC phosphorylation was assayed by using urea–glycerol electrophoresis and Western blot analysis, as previously described.31 In brief, cells grown on 60-mm Petri dishes were exposed to different drugs before protein was extracted with a urea sample buffer and subjected to electrophoresis. The separated phosphorylated MLC and nonphosphorylated MLC were detected by Western blot analysis with a specific anti-MLC antibody (E201; 1:3000). Scanned images of the bands were quantified by using a custom-made software program. The migration speeds of the mono-(P) and di-(PP) phosphorylated MLC and the nonphosphorylated (NP) form of MLC are as follows: PP > P > NP. The pixel intensity of each band was quantified by densitometry, and the fraction of p-MLC was calculated by dividing the total p-MLC (equal to the sum of P + PP) by total MLC (given by P + PP + NP). Treatment with thrombin was used as a positive control, since its effects on MLC phosphorylation are well understood.32–35

Staining of Actin Cytoskeleton

BCECs grown on glass coverslips were washed with PBS after drug treatment, fixed for 10 minutes with 3.7% paraformaldehyde/PBS, and permeabilized for 5 minutes with 0.2% Triton X-100/PBS. Cells were then incubated with Texas red–conjugated phalloidin (1:500; Invitrogen-Gibco) in the dark for 45 minutes at RT. Coverslips were mounted with an antifade agent containing 4-phenylmethyleneimine (Invitrogen-Molecular Probes) and viewed by fluorescence microscopy (λex = 542 nm and λem = 565 nm).

Adhesion Assay

Ninety-six-well tissue culture plates were coated with a mixture of 10 μg/mL fibronectin and 35 μg/mL collagen I (AtheneES, Baltimore, MD). BCECs (1 × 105 cells) suspended in serum-free DMEM/F12 were then plated and allowed to attach for 90 minutes at 37°C. Nonadherent cells were removed by gently washing four times with 200 μL growth medium. Attached cells were detected by incubating with 0.6 μM calcine-AM (Vybrant cell adhesion assay kit; Invitrogen-Molecular Probes) for 30 minutes at 37°C. The dye is hydrolyzed to hydrophilic calcine that is retained in viable cells. The number of cells was quantified as fluorescence of calcine measured with a microplate reader (λem = 494 nm and λem = 517 nm; FLUOstar; BMG, Offenburg, Germany).

RhoA Activation Assay

An absorbance-based ELISA technique (RhoA G-LISA kit; Cytoskeleton, Denver, CO) was used to quantify the effect of BAK. Cells in 60-mm Petri dishes first received 0.5% serum treatment for 24 hours and were then serum-starved for 16 to 18 hours before drug treatment. RhoAGDP in cell lysate was allowed to bind to the wells coated with a Rho-GTP-binding protein for 30 minutes. Inactive RhoA-GDP was removed by agitated washing. Bound RhoA-GTP was detected with a RhoA-specific antibody and an HRP-labeled secondary antibody. After the reaction was stopped, absorbance was measured at 490 nm with a spectrophotometer (DU-64; Beckman Coulter, Fullerton, CA).

ATP Release Assay

ATP release was assessed in real-time using the luciferase-luciferin (LL) bioluminescence technique. The luminometer was custom built around a cooled photomultiplier tube (H7422P-40; Hamamatsu Inc., Bridgewater, NJ). Cells grown on 35-mm Petri dishes and bathed in 600 μL medium (Opti-MEM I; Invitrogen-Gibco) containing 4 mg/mL LL were placed in proximity to the cathode of the photomultiplier. The luminescence emitted on ATP release and the subsequent oxidation of luciferin, passing through the bottom of the Petri dish to the cathode of the photomultiplier. The output of the photomultiplier in the form of voltage pulses was counted by a high-speed (80 MHz) timer–counter interface in a PC (NI-6602; National Instruments, Austin, TX). Independent calibration experiments in cell-free Petri dishes showed a linear increase in luminescence count with increasing ATP content over four orders of magnitude (10–13–10–9 moles; 66 counts/picomole; r = 0.99).
Flow Cytometry Analysis of Cell Death

An annexin V-FITC apoptosis kit (BioVision; Mountain View, CA) was used to detect dead cells. After treatment with BAK, cells were trypsinized and incubated in dark for 5 minutes with annexin V-FITC (1:250). Next, the cells were washed with annexin-binding buffer followed by incubation with propidium iodide (PI; 1:250) in dark for 5 minutes. Annexin V detects apoptotic cells by binding to phosphati-
dylyserine (PS), which translocates to the outside surface of the plasma membrane during early stages of apoptosis. Propidium iodide penetrates into the cells, in which the plasma membrane is damaged, usually an indication that cells are undergoing necrosis. All measurements were performed on a flow cytometer (FACScan; BD Biosciences, San Jose, CA) using the system software for data analysis (CellQuest Pro; BD Bio-
sciences). For each sample, at least 10,000 events were analyzed.

Data Analysis

Data were analyzed by one-way ANOVA with the Bonferroni test for posttest analysis (Prism 4.0 for Windows; GraphPad Software Inc., San Diego, CA). For the G-LISA assay of RhoA activity, results were analyzed by densitometric analysis of the thrombin response. *Significant differ-
ence from the control. C, control; T, thrombin; Y, Y-27632; Ch, chelerythrine.

RESULTS

Expression of MLCK, RhoA, and Rho Kinase in BCECs

As the first step to characterize MLC phosphorylation in BCECs, we determined expression of MLCK, RhoA, and Rho kinase. RT-PCR showed a positive band at the expected band size of 740 bp for the transcript of MLCK (Fig. 1A). The corresponding protein expression was confirmed by Western blot analysis, as shown in Figure 1B (Epi). The band at 220 kDa corresponds to the vascular endothelial isoform of MLCK (EC-MLCK; 220 kDa). It is noteworthy that the corneal endothelial cells used as a positive control showed expression of both the smooth muscle (SM-
MLCK; 130 kDa) and EC-MLCK isoforms (Endo).

Transcripts of the small GTPase RhoA and its downstream effector Rho kinase I at the mRNA level are also found in BCECs. Figure 1A shows expected bands at 361 bp and 405 bp, corresponding to transcripts of RhoA and Rho kinase I, respecti-
vively.

Effect of BAK on MLC Phosphorylation

To secure functional evidence for MLCK, RhoA, and Rho kinase, we examined the response of BCECs to the protease activated receptor (PAR)-1 agonist, thrombin. PAR-1 receptors, we examined the response of BCECs to the protease activated receptor (PAR)-1 agonist, thrombin. PAR-1 receptors, coupled to G_{s12/13} G protein, mobilize the RhoA-Rho kinase axis.30 This has been demonstrated in BCECs in one of our recent studies.31 As shown in Figure 2, when epithelial cells were exposed to thrombin (2 U/mL; 2 minutes), a significant increase in p-MLC (125.6%, n = 5) was noticed. Cells also showed a significant level of MLC phosphorylation under basal conditions (Fig. 2A; C). The thrombin response was inhibited by pre-exposure to the Rho kinase inhibitor, Y-27632 (10 μM; 30 minutes; p-MLC = 35.6%, n = 4) or the PKC inhibitor, chelerythrine (10 μM; 10 minutes; p-MLC = 103.9%, n = 4). These inhibitors also reduced the basal level of MLC phosphorylation (Y-27632, 15.7%; n = 4; chelerythrine, 65.8%, n = 4). A summary plot of these findings is shown in Figure 2B. These results, taken together, not only provide functional evidence for RhoA-mediated MLC phosphorylation in BCECs for the first time, but also establish the MLC assay protocol.

Using the same protocol, we next examined the effect of BAK on MLC phosphorylation on its exposure for 10, 20, and 30 minutes. A typical urea-glycerol gel electrophoresis followed by Western blot analysis. (A) A typical gel showing thrombin-induced MLC phosphorylation (lane T) which was inhibited by Y-27632 (10 μM, 30 minutes; lane T+Y) and chelerythrine (10 μM, 10 minutes; lane T+Ch). BCECs showed a basal level of MLC phosphorylation under control conditions (lane C). Both Y-27632 and chelerythrine inhibit this basal MLC phosphorylation (lanes Y, Ch). (B) A summary of the densitometric analysis of the thrombin response. *Significant differ-
ence from the control.

Figure 1. Expression of MLCK in cultured BCECs. (A) RT-PCR analysis showed a positive band at the expected size for MLCK (740 bp). Transcripts of RhoA and Rho kinase 1 were also found at the expected sizes of 361 and 405 bp, respectively. GAPDH was the positive control (430 bp). (B) Western blot analysis indicated expression of the EC iso-
form of MLCK (220 kDa) in BCEC. Epi, epithelial cells; Endo, endothelial cells.

Figure 2. Thrombin-induced MLC phosphorylation in BCECs. The cells were exposed to thrombin (2 U/mL; 2 minutes) and then were subjected to urea glycerol gel electrophoresis followed by Western blot analysis. (A) A typical gel showing thrombin-induced MLC phosphorylation (lane T) which was inhibited by Y-27632 (10 μM, 30 minutes; lane T+Y) and chelerythrine (10 μM, 10 minutes; lane T+Ch). BCECs showed a basal level of MLC phosphorylation under control conditions (lane C). Both Y-27632 and chelerythrine inhibit this basal MLC phosphorylation (lanes Y, Ch). (B) A summary of the densitometric analysis of the thrombin response. *Significant differ-
e
or 0.0005% (there was no significant effect at the concentrations of 0.001% and 0.003%) for different exposure time. (A) A representative urea-glycerol gel showing significant MLC dephosphorylation at 10, 20, and 30 minutes induced by 0.003% BAK. (B) A summary plot of the densitometric analysis of the BAK response. *Significant difference from the control of the group (P < 0.05).

(n = 5) within 10 minutes. The dephosphorylation was 60% at 30 minutes (60% ± 10%; n = 5). At lower concentrations, BAK caused relatively reduced dephosphorylation. At 10 minutes, there was no significant effect at the concentrations of 0.001% or 0.0005% (P > 0.05). However, at 20 minutes, MLC dephosphorylation was significantly different from the control (0.001% BAK: 37% ± 9%, n = 6; and 0.0005% BAK: 32% ± 6%, n = 6), and this lasted for at least 30 minutes (36% ± 13% for 0.001% BAK and 27% ± 6% for 0.0005% BAK; n = 6).

Effect of BAK on Actin Cytoskeleton
MLC phosphorylation promotes actomyosin interaction and actin reorganization. In corneal endothelium, MLC phosphorylation led to disruption of cortical actin and development of interendothelial gaps. We examined organization of the actin cytoskeleton in response to BAK using phalloidin (conjugated to Texas Red) staining. The untreated cells showed a dense web of cortical actin (Fig. 4A), which has often been referred to as the perijunctional actomyosin ring (PAMR). BAK, at the concentration of 0.001%, caused thinning of the cortical actin bundles (Fig. 4B). The effect became more prominent at 0.003% (Fig. 4C).

Effect of BAK on Cell Adhesion
Reduced actin contractility is known to cause loss of integrin-mediated focal adhesion of cells. Consistent with MLC dephosphorylation, which indicates a decrease in actin contractility, BAK induced a significant reduction in cell adhesion. As shown in Figure 5, coating of culture plates with a cocktail of fibronectin and collagen I increased cell adhesion by 28% (n = 10; P < 0.001). However, even with coating, cell adhesion was reduced by 42% (n = 10; P < 0.001) in response to 0.001% BAK. No effect of BAK was found at 0.0001% (n = 10; P > 0.05).

Effect of BAK on RhoA
Since the RhoA-Rho kinase axis plays a key role in MLC phosphorylation and consequently in the regulation of actin cytoskeleton at focal adhesions, we examined RhoA activity with BAK treatment. The immunoprecipitation results showed negligible RhoA activity in serum-starved control cells (Fig. 6, Control). Thrombin (2 U/mL; 2 minutes), used as a positive control, caused a 1.5-fold increase (n = 5, P < 0.05) in RhoA activity (Fig. 6, T). Instead of the inhibition of RhoA, as suggested by MLC dephosphorylation data (Fig. 3), 0.001% BAK led to a 1.8-fold increase in RhoA activity (n = 5, P < 0.05; Fig. 6, BAK). No additive effect was seen with cotreatment of BAK and thrombin.

ATP Release Induced by BAK
BAK is known to cause ATP depletion in corneal epithelial cells. However, effect has been reported only at the high concentration of 0.01%, and the underlying mechanism has not been explored. Accordingly, we examined ATP release in real-time at lower concentrations of BAK, by using the luciferase-luciferin bioluminescence technique. As shown in Figure 7A, both 0.001% and 0.003% BAK caused a precipitous increase in the luminescence count. The luminescence signal declined exponentially after the peak but lasted at least for several minutes. The peak ATP release averaged 65 ± 19 nM (n = 15) with 0.001% BAK and 102 ± 16 nM (n = 15) with 0.003% BAK, as summarized in Figure 7B.

MLC Phosphorylation on ATP Depletion
Since BAK led to an acute loss of intracellular ATP concomitant with MLC dephosphorylation, we examined MLC phosphorylation and consequently in the regulation of actin cytoskeleton at focal adhesions, we examined RhoA activity with BAK treatment. The immunoprecipitation results showed negligible RhoA activity in serum-starved control cells (Fig. 6, Control). Thrombin (2 U/mL; 2 minutes), used as a positive control, caused a 1.5-fold increase (n = 5, P < 0.05) in RhoA activity (Fig. 6, T). Instead of the inhibition of RhoA, as suggested by MLC dephosphorylation data (Fig. 3), 0.001% BAK led to a 1.8-fold increase in RhoA activity (n = 5, P < 0.05; Fig. 6, BAK). No additive effect was seen with cotreatment of BAK and thrombin.
BAK-Induced MLC Dephosphorylation

**DISCUSSION**

BAK is a widely used preservative in topical ophthalmic formulations, and its side effects on the cornea have been frequently investigated. In this study, our main goal was to understand the molecular mechanisms by which BAK induces a loss in the barrier integrity of the corneal epithelium. Our principal finding is that BAK, at subclinical concentrations, induces significant MLC dephosphorylation in cultured BCECs. Since phosphorylated MLC induces actomyosin interaction, BAK's effect is indicative of a loss in contractility of the actin cytoskeleton. In terms of cell biological activities, this implies that BAK could affect cell adhesion, cell movement, and proliferation, as per the XYZ hypothesis, we suggest that the side effects of BAK can be traced to a compromised actin cytoskeleton.

**Contractility of the Actin Cytoskeleton**

Our recent studies in corneal endothelium have demonstrated a disruption of the barrier integrity as a result of increased actin contractility in response to inflammatory agonists. This was attributed to a loss of the intercellular tethering forces that maintain interactions of the transmembrane proteins at tight junctions. In the absence of such interactions, occlusion of the paracellular space is prevented and a loss of the barrier integrity becomes inevitable. The loss of the intercellular tethering forces, per se, is due to an increase in the contractility of the cortical actin cytoskeleton (PAMR, see Fig. 4A) which results in a net centripetal force.

Given that BAK is well known to induce a loss in the barrier integrity of the corneal epithelium, it was intriguing to deter-
mine whether the preservative affected MLC phosphorylation and actin contractility. We examined phosphorylation of MLC using a protocol involving urea-glycerol gel electrophoresis for separating the phosphorylated and nonphosphorylated forms of MLC followed by Western blot analysis for identification. This protocol has been established in our previous studies on corneal endothelial cells. Since there have been no reports on MLC phosphorylation in corneal epithelial cells, we used thrombin as a positive control. It is known to induce MLC phosphorylation in corneal endothelial cells through G_{12/13} G protein–coupled PAR-1 receptors, which activates the RhoA-Rho kinase axis. Consistent with the presence of PAR-1 receptors in corneal epithelial cells, we observed significant MLC phosphorylation after treatment with thrombin (Fig. 2). In addition, we examined the expression of MLCK, RhoA, and Rho kinase. The positive results (Fig. 1) support the thrombin-induced MLC phosphorylation observed in BCECs (Fig. 2). It is worth noting that MLCK showed a differential expression of its two isoforms in corneal epithelial cells compared with corneal endothelial cells (Fig. 1B). Only the versatile EC-MLCK, which is the vascular endothelial isoform susceptible to modulation by several protein kinases, was found in the epithelial cells.

**Effects of BAK on the Actin Cytoskeleton**

Applying the same protocol as for thrombin, we next examined the status of MLC phosphorylation in response to BAK at several subclinical concentrations. At all the concentrations examined, BAK consistently induced MLC dephosphorylation at the different time points of observation (Fig. 3), without causing significant cell death (Fig. 9). This finding suggests that the loss of barrier integrity caused by the preservative is not through increased actin contractility. Despite this unexpected finding, BAK induced two other significant effects related to the actin cytoskeleton concomitantly with MLC dephosphorylation: thinning of the cortical actin (Fig. 4) and loss of cell adhesion (Fig. 5). These effects are similar to what has been reported in response to ATP depletion in other epithelial cell types. The thinning of the cortical actin, presumably due to severing and depolymerization of the actin filaments, may have significant impact on the intercellular tethering forces or the barrier integrity. The cortical actin is known to attach to a variety of linker proteins at the tight and adherence junctions. Thus, a treatment with cytochalasin, an actin-severing–disrupting drug, is known to affect the tight junction complex and eventually break down epithelial permeability. Similarly, it is plausible that the loss of actin filaments in response to BAK contributes to a disintegration of the molecular assembly at the junctional complexes, resulting in a breakdown of the barrier integrity of the corneal epithelium.

**Mechanisms Contributing to MLC Dephosphorylation**

MLC phosphorylation is positively influenced by Ca^{2+}–dependent MLCK activity and negatively by Ca^{2+}–independent MLCP (Fig. 10). Therefore, our observation that BAK induces RhoA activation concomitantly with MLC dephosphorylation is unexpected. The observed RhoA activation, however, can be attributed to the release of RhoGEFs as a result of BAK-induced direct activation of G proteins through nonspecific interactions during membrane damage, and membrane depolarization through activation of nonspecific cation channels. Many G proteins are known to mediate RhoA activation via RhoGEFs. ROS is also implicated in the release of RhoGEFs through microtubule depolymerization. Although depolarization of the membrane potential is known to induce RhoA-Rho kinase–dependent disruption of actin cytoskeleton, the mechanism for concomitant release of RhoGEFs is not known. Thus, leaving out inhibition of RhoA as a potential mechanism, we can attribute BAK-induced MLC dephosphorylation to either inhibition of MLCK.
or a decrease in the phosphorylation potential due to cellular ATP depletion.

A potential loss of MLCK activity cannot be attributed to the depletion of intracellular free Ca^{2+} ([Ca^{2+}]), since BAK is likely to elevate [Ca^{2+}], through activation of nonselective cation channels.52 However, direct effect on the activity of MLCK cannot be ruled out. As regards the intracellular ATP level, there is ample evidence for BAK-induced ATP depletion. Our results clearly show that the depletion could be due to a direct release of ATP (Fig. 7). Furthermore, deliberate ATP depletion by hypoxia and antimycin A treatment also led to MLC dephosphorylation similar to BAK treatment (Fig. 8).

In summary, BAK causes MLC dephosphorylation at concentrations lower than 0.005% in BCECs, possibly through the inhibition of MLCK and/or a reduced phosphorylation potential for activity of kinases concomitant with ATP loss. MLC dephosphorylation, which implies reduced actin contractility, could impair those cellular functions that contribute to the maintenance of the epithelial barrier. Further investigation is needed to demonstrate the significance of the findings in vivo.

**References**


